Post-COVID-19 Conditions Among Children 90 Days After SARS-CoV-2 Infection
Overview
Authors
Affiliations
Importance: Little is known about the risk factors for, and the risk of, developing post-COVID-19 conditions (PCCs) among children.
Objectives: To estimate the proportion of SARS-CoV-2-positive children with PCCs 90 days after a positive test result, to compare this proportion with SARS-CoV-2-negative children, and to assess factors associated with PCCs.
Design, Setting, And Participants: This prospective cohort study, conducted in 36 emergency departments (EDs) in 8 countries between March 7, 2020, and January 20, 2021, included 1884 SARS-CoV-2-positive children who completed 90-day follow-up; 1686 of these children were frequency matched by hospitalization status, country, and recruitment date with 1701 SARS-CoV-2-negative controls.
Exposure: SARS-CoV-2 detected via nucleic acid testing.
Main Outcomes And Measures: Post-COVID-19 conditions, defined as any persistent, new, or recurrent health problems reported in the 90-day follow-up survey.
Results: Of 8642 enrolled children, 2368 (27.4%) were SARS-CoV-2 positive, among whom 2365 (99.9%) had index ED visit disposition data available; among the 1884 children (79.7%) who completed follow-up, the median age was 3 years (IQR, 0-10 years) and 994 (52.8%) were boys. A total of 110 SARS-CoV-2-positive children (5.8%; 95% CI, 4.8%-7.0%) reported PCCs, including 44 of 447 children (9.8%; 95% CI, 7.4%-13.0%) hospitalized during the acute illness and 66 of 1437 children (4.6%; 95% CI, 3.6%-5.8%) not hospitalized during the acute illness (difference, 5.3%; 95% CI, 2.5%-8.5%). Among SARS-CoV-2-positive children, the most common symptom was fatigue or weakness (21 [1.1%]). Characteristics associated with reporting at least 1 PCC at 90 days included being hospitalized 48 hours or more compared with no hospitalization (adjusted odds ratio [aOR], 2.67 [95% CI, 1.63-4.38]); having 4 or more symptoms reported at the index ED visit compared with 1 to 3 symptoms (4-6 symptoms: aOR, 2.35 [95% CI, 1.28-4.31]; ≥7 symptoms: aOR, 4.59 [95% CI, 2.50-8.44]); and being 14 years of age or older compared with younger than 1 year (aOR, 2.67 [95% CI, 1.43-4.99]). SARS-CoV-2-positive children were more likely to report PCCs at 90 days compared with those who tested negative, both among those who were not hospitalized (55 of 1295 [4.2%; 95% CI, 3.2%-5.5%] vs 35 of 1321 [2.7%; 95% CI, 1.9%-3.7%]; difference, 1.6% [95% CI, 0.2%-3.0%]) and those who were hospitalized (40 of 391 [10.2%; 95% CI, 7.4%-13.7%] vs 19 of 380 [5.0%; 95% CI, 3.0%-7.7%]; difference, 5.2% [95% CI, 1.5%-9.1%]). In addition, SARS-CoV-2 positivity was associated with reporting PCCs 90 days after the index ED visit (aOR, 1.63 [95% CI, 1.14-2.35]), specifically systemic health problems (eg, fatigue, weakness, fever; aOR, 2.44 [95% CI, 1.19-5.00]).
Conclusions And Relevance: In this cohort study, SARS-CoV-2 infection was associated with reporting PCCs at 90 days in children. Guidance and follow-up are particularly necessary for hospitalized children who have numerous acute symptoms and are older.
An online survey among convalescents 5 months post SARS-CoV-2 infection in China.
Wang Y, Liu M, Guo Y, Li M, Guo P, He W Biosaf Health. 2025; 6(4):206-215.
PMID: 40078662 PMC: 11894947. DOI: 10.1016/j.bsheal.2024.06.001.
Wan L, Liu Y, Tan S, Xiao J, Feng B, Fang J BMJ Open. 2025; 15(3):e089651.
PMID: 40032399 PMC: 11877153. DOI: 10.1136/bmjopen-2024-089651.
Putri N, Laksanawati I, Husada D, Kaswandani N, Prayitno A, Triasih R PLoS One. 2025; 20(3):e0315815.
PMID: 40029921 PMC: 11875387. DOI: 10.1371/journal.pone.0315815.
COVID-19 Vaccination and Odds of Post-COVID-19 Condition Symptoms in Children Aged 5 to 17 Years.
Yousaf A, Mak J, Gwynn L, Lutrick K, Bloodworth R, Rai R JAMA Netw Open. 2025; 8(2):e2459672.
PMID: 39992656 PMC: 11851240. DOI: 10.1001/jamanetworkopen.2024.59672.
Postacute COVID-19 fatigue, dyspnea and reduced activity in children and adolescents.
Lin C, Chen K, Wu J, Liu Y, Yen T, Lu C Pediatr Res. 2025; .
PMID: 39900834 DOI: 10.1038/s41390-025-03897-2.